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Abstract
Epileptic Encephalopathy (EE) is a heterogeneous condition in which cognitive, sensory
and/or motor functions deteriorate as a consequence of epileptic activity, which consists of
frequent seizures and/or major interictal paroxysmal activity. There are various causes of
EE and they may occur at any age in early childhood. Genetic mutations have been identi-
fied to contribute to an increasing number of children with early onset EE which had been
previously considered as cryptogenic. We identified 26 patients with Infantile Epileptic En-
cephalopathy (IEE) of unknown etiology despite extensive workup and without any specific
epilepsy syndromic phenotypes. We performed genetic analysis on a panel of 7 genes
(ARX, CDKL5, KCNQ2, PCDH19, SCN1A, SCN2A, STXBP1) and identified 10 point muta-
tions [ARX (1), CDKL5 (3), KCNQ2 (2), PCDH19 (1), SCN1A (1), STXBP1 (2)] as well as
one microdeletion involving both SCN1A and SCN2A. The high rate (42%) of mutations
suggested that genetic testing of this IEE panel of genes is recommended for cryptogenic
IEE with no etiology identified. These 7 genes are associated with channelopathies or syn-
aptic transmission and we recommend early genetic testing if possible to guide the treat-
ment strategy.
Introduction
Epileptic Encephalopathy (EE) is a heterogeneous condition in which cognitive, sensory and/or
motor functions deteriorate as a consequence of epileptic activity, which consists of frequent sei-
zures and/or major interictal paroxysmal activity [1]. This concept was formally recognized in
2001 and subsequent International League Against Epilepsy (ILAE) reports. The 2010 report of
the ILAE Commission on Classification and Terminology stated that “Epileptic Encephalopathy
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embodies the notion that the epileptic activity itself may contribute to severe cognitive and be-
havioral impairments above and beyond what might be expected from the underlying pathology
alone. These impairments may be global or more selective and they may occur along a spectrum
of severity [2]”. EE may occur at any age, but the phenomenon is most common and severe in in-
fancy and early childhood, which is the most critical period of brain maturation [3]. However,
many neonates or infants with EE do not fit into any of the proposed epileptic syndromes [4].
Etiologies for EE can be due to 1) congenital structural brain abnormalities, 2) metabolic
diseases, 3) recognizable dysmorphic syndromes, 4) non-syndromic monogeneic causes, or 5)
environmental causes [5]. Structural brain abnormalities, either congenital (such as cortical
malformations) or acquired (such as hypoxic ischemic insults), are the most common cause of
early onset EE [4]. However, in approximately one third of patients with EE, the underlying
cause remains unknown after extensive investigations [6].
With the advancement of gene diagnostics technology, genetic defects have been increasing-
ly recognized as causes of early onset EEs previously considered cryptogenic. Genes including
ARX, CDKL5, KCNQ2, PCDH19, SCN1A, SCN2A and STXBP1 involved in ion channelopa-
thies, neuronal transmission, brain development or synaptic functions were reported to be as-
sociated with EEs. [7]. Previously, these genes were only found to be associated with specific
epilepsy syndromes, but recent reports widened the clinical spectrum of these gene-associated
disorders. For example, KCNQ2mutations have been reported in benign familial neonatal sei-
zures (BFNS) and in severe neonatal EE (NEE) with quadriplegia and Ohtahara syndrome [8–
12]. STXBP1mutations were first reported in patients with Ohtahara syndrome [13] and later
identified in patients with infantile spasm, DS, West syndrome and nonsyndromic early onset
EE [14–16] and quadriplegia [13].
As the clinical phenotype for these gene-associated EEs was expanding and overlapping,
there was an anticipated difficulty in selecting only one candidate gene for molecular evalua-
tion in patients with EE who did not fit into any epilepsy syndrome classified according to
ILAE. We had therefore selected 7 genes (ARX, CDKL5, KCNQ2, PCDH19, SCN1A, SCN2A,
and STXBP1) for screening our patients with non-syndromic Infantile Epileptic Encephalopa-
thies (IEE) after extensive metabolic and neuroimaging workup had been negative. These
genes have been associated for years with a fairly well-established spectrum of clinical pheno-
types. They play a critical role in neurotransmission and synaptic function, which could be an
important mechanism of IEE. Identification of an underlying genetic cause is essential to pro-
vide information on prognosis and avoid unnecessary investigations. Moreover, the possibility
of prenatal diagnosis and selection of appropriate anticonvulsants might follow.
Methods
Ethics Statement
This study was approved by the Institutional Review Board of the Hong Kong West Cluster
and the University of Hong Kong (IRB Ref. No.: UW 11–190). Written consent was obtained
from the parents of our patients.
Patient samples and clinical diagnosis
The study was conducted in Queen Mary Hospital and Duchess of Kent Children Hospital,
two affiliated hospitals of The University of Hong Kong. We included patients who satisfied
the ILAE definition of EE and with seizure onset before 24 months of age. According to the
ILAE Commission on Classification and Terminology, infants are referred to those less than
one year of age [2]. We had included children with seizure onset before the age of two years in
order to capture those with late IEE [17] or IEE with late onset spasms [18]. We excluded
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patients with definite evidence of brain insult, confirmed disorder of cortical development by
magnetic resonance imaging, neurocutaneous disorders, syndromal disorders and confirmed
or highly suspected neurometabolic disorders based on clinical (multi-system involvement in-
cluding organomegaly or skeletal changes) and biochemical markers. Extensive neurometa-
bolic evaluations conducted for all these patients were negative (blood for amino acid,
biotinidase, ammonia, lactate, glucose, very long chain fatty acids including phytanic and pris-
tanic acids, transferrin isoform electrophoresis, total homocysteine, copper, coeruloplasmin,
creatine and guanadinoacetate; urine for purine and pyrimidine screening, creatine, guanadi-
noacetate and organic acid; cerebrospinal fluid for glucose, lactate, protein, amino acid, neuro-
transmitters and 5-methyltetrahydrofolate). All patients failed to show any positive response to
a trial of intravenous pyridoxine up to 300 mg under electroencephalography monitoring, fol-
lowed by adequate trials of oral pyridoxine, pyridoxal phosphate and folinic acid [19]. We also
excluded patients who fit into distinct electroclinical syndromes proposed by the ILAE and
those not actively followed up in our centre.
Data variables collected from the medical charts included demographic information (gen-
der, ethnicity, age at seizure onset and latest follow up), family history (febrile convulsion, epi-
lepsy, intellectual disability and other neurological diseases), epilepsy details (seizure types at
onset and latest follow up, seizure frequency and evolution, history of status epilepticus, anti-
epileptic medications used), neurological examination findings (upper motor neuron syn-
drome, hypotonia, movement disorders [dystonia, choreoathetosis, myoclonus, ataxia, parkin-
sonism], microcephaly, macrocephaly, dysmorphism), investigations (MRI brain and EEG
results), mortality and other associated clinical features (autism spectrum disorder and other
neurobehavioral disorders such as attention deficit hyperactivity disorder, visual impairment,
hearing impairment, ability of independent walking and oromotor dysfunction requiring naso-
gastric tube or gastrostomy feeding). Information regarding the developmental status at the
time of seizure onset and latest follow up was collected as well. Either formal neuropsychologi-
cal testing (using Griffiths Mental Developmental Scale or HK-WISC) or best clinical assess-
ment (based on developmental milestones recorded in the medical charts) were used to classify
development or intelligence as normal, mildly delayed, moderately delayed or severely delayed.
All patients were screened for mutations of 6 genes (ARX, CDKL5, KCNQ2, SCN1A, SCN2A
and STXBP1). Mutation analysis of PCDH19 was only performed in female patients as the
PCDH19-associated X-linked IEE mainly affect female with heterozygous mutations.
Point mutation analysis
Genomic DNA samples of the patients were extracted from peripheral blood using Flexigene
DNA Kit (Qiagen GmbH, Germany). All exons covering the coding regions as well as the splice
junctions were amplified by polymerase chain reaction (PCR) using oligonucleotide primers
designed based on the reference genomic sequence (Table 1) of different genes. PCR contained
0.1 μg of genomic DNA as template, 5 pmol of each primer, 200 μM of deoxyribonucleoside tri-
phosphates, and 0.5 U HotStarTaq Plus DNA polymerase (Qiagen) in 1X Qiagen PCR buffer.
PCR was carried out with initial enzyme activation at 95°C for 5 minutes, followed by 50 cycles
of denaturation at 94°C for 30 seconds, annealing at 60°C for 1 minute and extension at 72°C
for 1.5 minutes, with a final extension at 72°C for 10 minutes. For those templates with high de-
gree of secondary structures or high GC-contents, 1x Q-Solution (Qiagen) was included in the
PCR mixtures. If the non-specific products could not be eliminated by adding Q-Solution, a
higher initial activating temperature of 98°C and denaturing temperature of 96°C were used
(Table 1). The quality and quantity of PCR products were checked by agarose gel electrophore-
sis. PCR products were directly used for sequencing reaction by Bigdye Terminator v3.1 Cycle
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Sequencing Kit (Applied Biosystem, Foster City, CA) and analyzed on a 3730xl DNA analyzer
(Applied Biosystems).
Homology analyses with the reference genomic sequence (Table 1) were performed using
NCBI program BLAST. The numbering for each mutation was taken from the start codon with +1
corresponding to the A of the ATG in the reference sequence (Table 1). Mutations were discrimi-
nated from single nucleotide polymorphisms (SNP) with allele frequency> 0.01 reported in NCBI
SNP and Ensembl SNP database. The parental DNA was collected and sequenced to distinguish
between de novo and familial variants.
Pathogenicity assessment of the mutations
Evolutionary conservation analysis was performed to predict whether the amino acid substitu-
tion in missense mutations would affect protein function based on the degree of conservation
at the affected residues. Besides, online sequence homology-based tool, Sorting Intolerant from
Tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2) and Align-Grantham variation/
Grantham deviation (Align-GVGD) analysis have been used to predict whether the mutation
would interfere with the protein function. We have described them previously [20]. The two
splice site mutations in intron regions were analyzed by another online software tool, the Auto-
mated Splice Site Analyses (Laboratory of Human Molecular Genetics and Genomic Disorders,
UWO, CA, https://splice.uwo.ca/) [21].
Multiplex ligation-dependent probe amplification (MLPA)
For identification of copy number variations (CNVs) of the intragenic regions or entire genes,
MLPA was used. It made use of a single PCR primer pair for all the probes to determine the
copy number of all sequences in a single multiplex PCR based reaction followed by capillary
electrophoresis.
For the ARX, CDKL5, KCNQ2, PCDH19 and SCN1A genes, commercial MLPA probemixes
(SALSA P189 CDKL5 probemix for both CDKL5 and ARX, SALSA P166 KCNQ2 probemix for
KCNQ2 and SALSA P137 SCN1A probemix for SCN1A, MRC Holland, Amsterdam, The Neth-
erlands) as well as the SALSAMLPA reagent kit (MRC Holland) were used. For SCN2A and
STXBP1, commercial MLPA kits were not available and synthetic MLPA probes were designed
by the online software H-MAPD suggested by the protocol (http://bioinform.arcan.stonybrook.
edu/mlpa2/cgi-bin/mlpa.cgi) and synthesized for all the exons according to the guidelines and
Table 1. GenBank accession numbers, chromosome positions and PCR conditions for exon amplifications of the 7 IEE genes.
Gene GenBank accession no. Chromosome position Coding exons PCR conditions
Gene mRNA
ARX NG_008281 NM_139058 Xp21.3 Exon 1, 3–5 Higher temperature
Exon 2 Higher temperature and Q-solution added
CDKL5 NG_008475 NM_003159 Xp22 Exon 2–21 Default
KCNQ2 NG_009004 NM_172107 20q13.3 Exon 1, 6–7 Q-solution added
Exon 2–5, 8–16 Default
Exon 17 Higher temperature and Q-solution added
PCDH19 NG_021319 NM_001184880 Xq22 Exon 1–6 Default
SCN1A NG_011906 NM_001165963 2q24.3 Exon 1–26 Default
SCN2A NG_008143 NM_001040142 2q24.3 Exon 1–29 Default
STXBP1 NG_016623 NM_003165 9q34.1 Exon 1 Q-solution added
Exon 2–20 Default
doi:10.1371/journal.pone.0126446.t001
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protocol provided by MRCHolland. The MLPA procedures were performed according to the
manufacturer’s protocols. Fragment analysis of PCR products was performed on the ABI 3130xl
capillary sequencer (Thermo Fisher Scientific, Waltham, MA) by using GeneScan TM-500LIZ as
size standards (Thermo Fisher Scientific) and HiDi formamide (Thermo Fisher Scientific). The
GeneScan results were analyzed using Coffalyser software (MRCHolland). The peak area of a
given exon was divided by the sum of 12 reference peak areas for each individual sample. The
final ratio was obtained by dividing this relative peak area of the corresponding exon by the aver-
aged normal control peak area. Thresholds of<0.65 were set for deletions and>1.35 for
duplications.
Results
Clinical characteristics (Table 2)
Twenty-six IEE patients, whose etiology was unknown and who did not fit into specific electro-
clinical syndromes, were identified from our registry. The majority (24/26, 92%) of patients
were from Asia. Only 2 patients had an ethnic origin other than Asian. One was African-
French (patient 32). Another was Portuguese-Chinese (patient 44). The majority (21/26, 81%)
of the selected IEE cohort were pure Chinese.
The mean age of seizure onset was 4.1 months (SD 3.9 months), while the median was 3
months. Epileptic spasm was the most common type of seizure at onset. 10 out of 26 (38%) had
epileptic spasm as the first seizure type. Most of the children (92%) developed multiple types of
seizures with time. Concerning the seizure evolution, 16 patients (62%) had more than 50% sei-
zure reduction and 5 patients (18%) had 25–50% seizure reduction. Concerning neurodevelop-
ment, 19 patients (73%) were severely developmentally delayed at the latest evaluation. Seven
patients (27%) had developmental regression, which was considered to be the hallmark of EE
and was defined as loss of acquired skills. This was compatible with EE which has the tendency
to abate, discontinue or even stop, but often with serious neurocognitive deficits [22]. It was
worth noting that 10 patients (38%) had a movement disorder exclusively in the form of dysto-
nia, either generalized or focal and 7 patients (27%) had an upper motor neuron syndrome.
Mutation analysis
Eleven out of 26 patients (42%) were found to have mutations among the 7 genes (Fig 1 and
Table 2). All mutation details have been summarized in Table 3. Most of the variants were
identified to be truncating and only one of them (p.A40V) was a missense mutation. Evolution-
ary conservation analysis showed that the affected amino acid residue of this missense muta-
tion was highly conserved (Fig 1). SIFT, Polyphen-2 and Align-GVGD (Grantham variation: 0;
Grantham deviation: 65.28; Class 65) analyses predicted that the missense mutation is probably
damaging. Nine of the mutations were novel and the 2 CDKL5mutations have been reported
previously [23–26]. The three splice site mutations, IVS24-1G>T, IVS9-2A>G and IVS6
+1G>C, were predicted to form a leaky acceptor splice site, abolish the acceptor or donor
splice site respectively. There were no microdeletions or CNVs for ARX, CDKL5, KCNQ2,
PCDH19 and STXBP1 by MLPA analysis.
Discussion
High occurrence of mutations in our selected IEE gene panel
We had attempted to apply the panel approach of genetic testing on subjects with IEE. These
seven genes were reported to be involved in IEE. We found that the yield of the current gene
panel analysis on IEE patients with unknown etiology was up to 42%. This is also the first
Mutations of Neuronal and Synaptic Genes in IEE Patients
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Table 2. Clinical characteristics of 26 patients with infantile epileptic encephalopathies of unknown etiology.
Case
no.
Ethnic origin Sex/
Age
Mutation Age of
first
seizure
(months)
Type of
seizure
at
onset*
Seizure
types
developed*
Number
of regular
anti-
epileptic
drugs
Seizure
evolution
Development
at most recent
follow up
Associated
clinical features
2 Chinese M/3 STXBP1
frameshift
0.5 S G, M, S 5 >50%
reduction
Severe delay UMN signs;
dystonia;
microcephaly; CVI;
laryngomalacia;
failure to thrive
9 Chinese F/6 ARX
nonsense
1 F A, At, F, G,
M
4 >25% but
<50%
reduction
Severe delay UMN signs;
dystonia;
microcephaly; CVI
15 Chinese F/9 CDKL5
missense
3 F F 6 >50%
reduction
Severe delay Autism
25 Philippine F/12 CDKL5
nonsense
3 S G, M, S 10 >50%
reduction
Severe delay Dystonia; hand
stereotypies
28 Chinese F/4 KCNQ2
indels
<0.25 F F, G, S, O
(breath-
holding
attacks)
7 >50%
reduction
Severe delay UMN signs;
dystonia
30 Chinese M/14 KCNQ2
splice site
0.25 G F, G 2 Seizure
free
Mild delay Nil
32 African- French F/6 STXBP1
splice site
0.5 F F, G, S 7 >50%
reduction
Severe delay;
developmental
regression
Dystonia; CVI
33 Chinese F/18 PCDH19
frameshift
7 F, G F, G 4 Seizure
free
Mild delay Behavioral
problem
36 Chinese F/3 CDKL5
frameshift
10 G G, S 8 >25 but
<50%
reduction
Severe delay Nil
40 Chinese F/16 SCN1A
splice site
6 F F, G 10 >50%
reduction
Severe delay Nil
47 Chinese M/5 SCN1A &
SCN2A
whole
gene
deletion
2 F F, S, G, M 7 >50%
reduction
Severe delay;
developmental
regression
Microcephaly
1 Chinese F/9 Nil 6 At, M A, At, F, G,
M, S
6 >25% but
<50%
reduction
Severe delay;
developmental
regression
UMN signs
7 Chinese M/4 Nil 12 F F, G, M, O
(hypomotor
seizures)
3 >25% but
<50%
reduction
Moderate delay Microcephaly
8 Chinese F/15 Nil 7 S A, G, M, S 11 Static Severe delay;
developmental
regression
Autism; features of
Rett syndrome
12 Chinese M/3 Nil 3 S M, S 6 Static Severe delay Left foot dystonia;
microcephaly
13 Chinese M/6 Nil 6 G A, F, G, M 7 >50%
reduction
Severe delay;
developmental
regression
Microcephaly
18 Indian M/8 Nil 2 S G, M, S 6 >50%
reduction
Severe delay UMN signs;
Dystonia; CVI
(Continued)
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study on a cohort of mainly (81%) Chinese patients. Upon review of the clinical characteristics
of our patients with a positive mutation, no single or a group of clinical features could assist in
pinpointing a particular candidate gene for analysis. We found that of 10 patients (38%) with
dystonia, 5 were positive for one of the 5 gene mutations (ARX, CDKL5, KCNQ2, SCN2A and
STXBP1) and dystonia had not been highlighted as a key clinical feature for selecting genetic
mutations for IEE. As for those patients with mutations in the same gene, dystonia was not
necessarily present during the clinical evolution [25% (1 out of 4) in CDKL5; 50% (1 out of 2)
in KCNQ2; 100% (1 out of 1) in SCN2A, (1 out of 1) in ARX and (2 out of 2) in STXBP1].
Mutation in SCN1A, SCN2A & KCNQ2 for neuronal excitability
Ion channelopathies play a prominent role in the development of IEE. To date, more than 600
variants of SCN1A encoding for a voltage-gated sodium channel have been identified and most
mutations were found in patients with DS [27]. Our previous study identified more than 70%
of SCN1Amutations in a group of Chinese children with DS [20]. In contrast to SCN1A, much
fewer SCN2Amutations were reported in previous literatures. Mutations were recently
Table 2. (Continued)
Case
no.
Ethnic origin Sex/
Age
Mutation Age of
first
seizure
(months)
Type of
seizure
at
onset*
Seizure
types
developed*
Number
of regular
anti-
epileptic
drugs
Seizure
evolution
Development
at most recent
follow up
Associated
clinical features
20 Chinese M/4 Nil 6 S S 8 Static Severe delay UMN signs;
dystonia;
microcephaly;
oromotor
dysfunction
required
gastrostomy
21 Chinese F/15 Nil 8 S G, S 10 >50%
reduction
Mild delay;
developmental
regression
Autism; ADHD
23 Chinese F/2 Nil 4 G, M, S G, M, S 4 >50%
reduction
Severe delay Dystonia; CVI
24 Chinese M/3 Nil 0.25 S A, F, G, M, S 2 >50%
reduction
Severe delay UMN signs;
dystonia;
microcephaly
31 Singaporean-
Chinese and
Malaysian-
Chinese
F/7 Nil 0.25 F F, G 7 >50%
reduction
Severe delay Autism
34 Chinese M/
8m
Nil 4 F F, G 7 Static Severe delay;
developmental
regression
CVI
41 Chinese M/9 Nil <0.25 F F, S 5 >25 but
<50%
reduction
Mild delay Autism
44 Portuguese-
Chinese
M/3 Nil 14 At, G At, G 3 Static Moderate delay Nil
45 Chinese M/9 Nil 1 S F, G, S 2 >50%
reduction
Normal Nil
*S: spasm; M: myoclonic seizure; F: focal seizure with or without generalization; G: generalized tonic / clonic / tonic-clonic seizure; A: absence seizure; At:
atonic seizure; O: other seizure type.
doi:10.1371/journal.pone.0126446.t002
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identified in severe EE including DS, infantile spasm and Ohtahara syndrome [28–31]. Our
group also identified a SCN2A mutation in a patient with infantile spasm and severe intellectu-
al disability previously [32]. In the present study, one SCN1Amutation and one microdeletion
involving both SCN1A and SCN2A were identified. They were deleterious to the protein and
the abnormal sodium channel function leading to severe phenotypes could result from hap-
loinsufficiency as suggested previously [33, 34].
Mutations of KCNQ2 encoding the voltage-gated potassium channels were identified in pa-
tients with neonatal EE [8]. KCNQ2 is expressed in broad regions of the brain and the gene
Fig 1. Mutations of the ARX,CDKL5, KCNQ2, PCDH19, SCN1A, SCN2A and STXBP1 genes found in
the 10 patients and evolutionary conservation analyses for the missense mutation.
doi:10.1371/journal.pone.0126446.g001
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products form heteromultimeric channels that mediate the M-current that inhibit the neuronal
excitability [35]. Two IEE patients in the present study were found to have KCNQ2mutations.
The first mutation was a deletion-insertion mutation that replaced a short fragment LRPYD by
two amino acids (PT) in the protein. The short fragment (LRPYD) is located in a highly
Table 3. Variants of the ARX, CDKL5, KCNQ2, PCDH19, SCN1A, SCN2A and STXBP1 genes found in the 11 IEE patients.
Gene patient Type of
mutation
Exon Mutation Location in
protein
Inherited/
De novo
Reported/
Novel
Nucleotide Amino acid
ARX 9 Heterozygous
nonsense
2 c.869C>A p.S290X Upstream of
both paired-
homeodomain
and aristaless
domain
De novo Novel
CDKL5 15 Heterozygous
missense
4 c.119C>T p.A40V Located at the
ATP-binding
site
Parents’
DNA not
available
Reported
[23–26]
25 Heterozygous
nonsense
17 c.2494C>T p.Q832X Upstream of two
putative sites at
C-terminal
De novo Novel
36 Heterozygous
deletion
leading to
frameshift
16 c.2325-2326delGA p.K776fsX799 Upstream of
three putative
sites at C-
terminal
Parents’
DNA not
available
Reported
[23]
KCNQ2 28 Heterozygous
deletion and
insertion
(indels)
15 c.1676-
1688delTGCGGCCCTACGAinsCCAC
p.
L559-D563delinsPT
Highly
conserved
assembly
domain (A
domain) in C-
terminal
De novo Novel
30 Heterozygous
splice site
Intron
6
IVS6+1G>C - Junction
between exon 6
&7 is located at
transmembrane
domain 6
De novo Novel
PCDH19 33 Heterozygous
deletion
leading to
frameshift
3 c.2537-2538delAC p.N846fsX861 Located at
cytoplasmic
domain before
CM1 and CM2
motifs
Parents’
DNA not
available
Novel
SCN1A 40 Heterozygous
splice site
Intron
24
IVS24-1G>T - Junction
between
domain 3 & 4
Only
mother
DNA
available
with no
mutation
Novel
SCN1A
+SCN2A
47 One copy
deletion of the
entire SCN1A
and SCN2A
genes
all - - - De novo Novel
STXBP1 2 Heterozygous
deletion
leading to
frameshift
2 c.79delG p.E27fsX36 Domain 1 De novo Novel
32 Heterozygous
splice site
Intron
9
IVS9-2A>G - Domain 3a Parents’
DNA not
available
Novel
doi:10.1371/journal.pone.0126446.t003
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conserved domain (A-domain) of C-terminal of KCNQ2 necessary for subunit interactions to
form homo- or heteromeric channels to reach the surface [36, 37]. Another KCNQ2mutation
was a splice site mutation which may cause aberrant splicing and disrupt the protein at the po-
sition within transmembrane domain 6.
Mutation in PCDH19 & STXBP1 for synaptic transmission
PCDH19 belongs to the PCDHδ2 subgroup of PCDH family consisting of 6 extracellular cad-
herin (EC) repeats. It is involved in calcium-dependent cell-cell adhesion at the synaptic mem-
brane [38, 39] and it was hypothesized that the cellular interference was the main pathogenic
mechanism associated with PCDH19mutations [40]. Previously, we have identified PCDH19
mutations in two of our patients [20]. In the present study, a PCDH19 frameshift mutation (p.
N846fsX861) was identified. This mutation terminates the protein at the cytoplasmic domain
and abolishes the conserved CM1 and CM2 motifs [41, 42]. Wolverton & Lalande [42] sug-
gested that CM2 may play a functional role for mediating intracellular signal transduction.
STXBP1 encoding for the neural-specific syntaxin-binding protein has long been discovered
for regulation docking and fusion of synaptic vesicles through interaction with syntaxin in the
SNARE complex for neurotransmitter release [43, 44]. Until recently, STXBP1mutations were
identified to be associated with different forms of early-onset EE including Ohtahara syn-
drome, West syndrome and infantile spasms [7, 13–15]. STXBP1 is a horse-shoe shaped pro-
tein with 3 domains while domain 1 and 3a form the central cavity providing the binding
surface for syntaxin [45]. In the present study, c.79delG is a novel frameshift mutation forming
a stop codon in the early reading frame and IVS9-2A>G is a novel splice site mutation that
may possibly disrupt the protein at domain 3a necessary for syntaxin binding.
Role of CDKL5 and ARXmutation in synaptic development
The CDKL5 protein belongs to the family of serine/threonine kinases which is characterized by
an N-terminal catalytic domain [46]. In the past ten years, CDKL5mutations were found to be
associated with early-onset EE. In the present study, a relatively high percentage of CDKL5mu-
tations (14%) was found in non-syndromic IEE patients. p.A40V found in the present study is
one of the mutation hot-spots located at the highly conserved ATP-binding site (amino acid
14–47) of the catalytic domain reported previously in 4 different studies including 5 patients
[23–26].
Although mutation hot-spots were found in the catalytic domain, many pathological alter-
ations can still be found in the C-terminal region [46]. The frameshift (p.K776fsX799) and
nonsense (p.Q832X) mutations identified in the present study may cause truncation of the C-
terminus. The 2 truncating mutations located upstream from 2 and 3 putative sites which are
essential for the cellular localization of the protein [47]. Evidence was provided previously that
the C-terminus of CDKL5 is a negative regulator of catalytic activity of CDKL5 and required
for a proper subnuclear localization by protein-protein interactions [47–49]. p.K776fsX799 has
been reported previously and immunofluorescence data of the same study demonstrated that
the truncated protein mislocalized to the cytoplasm [23]. The important role of CDKL5 for
proper brain function and development elucidate the relationship of CDKL5mutations with
neurodevelopmental disorders.
ARX encodes an important transcription factor that plays a significant role in the neuronal
development of the brain [50]. In the present study, a heterozygous ARXmutation has been
found in a female IEE patient with multiple seizure types, spastic dystonic quadriplegia and se-
vere developmental delay. Although most affected females with ARXmutations showed rela-
tively mild clinical outcomes as compared to males, severe cases were reported previously with
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various outcomes [51, 52]. These cases may have occurred due to skewed X-inactivation or
post-zygotic mosaicism [52]. Further studies will be performed to illustrate the pattern of X-in-
activation in the patient. The previous literature reported ARXmutation associated with IEE in
female only rarely and only 2 cases with truncating ARXmutations have been reported previ-
ously [51, 53].
Association of the seven IEE genes with synaptic transmission
In the present study, mutations were found in the genes involved in neuronal excitability
(KCNQ2, SCN1A, and SCN2A), synaptic transmission (PCDH19, STXBP1) and synapse devel-
opment (ARX, CDKL5). The study of relationship between neurotransmitter release and ion
channels illustrated that impairment in structure and function of ion channels can actually
modulate the synaptic transmission by changing the synaptic terminal excitability [54, 55]. The
genetic defects found in the 7 genes may contribute directly or indirectly to the malfunction of
synaptic transmission that may be an important mechanism for IEE. A recent comprehensive
exome-sequencing study suggested that dysregulation of synaptic transmission plays an impor-
tant role in the pathogenesis of EE as they demonstrated a significant enrichment of de novo
mutations in genes annotated to be involved in synaptic transmission by pathway analysis [56].
Recommended diagnostic flow for patients with IEE
Based on the findings in our study, we propose a diagnostic algorithm for patients with IEE.
Through clinical history taking, physical examination and neuroimaging (magnetic resonance
imaging of the brain), relatively straightforward etiologies can be identified. If an underlying
etiology is still unknown, a detailed neurometabolic evaluation should be performed especially
aiming for potentially treatable causes such as vitamin-responsive epilepsies. This should in-
volve an adequate trial (dosage and duration) of pyridoxine, pyridoxal phosphate and folinic
acid. For those patients still without an underlying cause found, molecular workup is recom-
mended. Candidate gene(s) testing can be performed according to the recommendation by
Ottman et al [57] if a patient fits into a certain electroclinical syndrome. Otherwise, depending
on the availability of resources, mutation analysis of our selected panel of genes (ARX, CDKL5,
KCNQ2, PCDH19, SCN1A, SCN2A and STXBP1) is an option which can have a yield of up to
42%. Sanger sequencing of the selected gene panel is a relatively simple and direct method
which do not require various steps of library preparation and target capturing, platforms for
next generation sequencing, bioinformatics and various filtering strategies. Besides, the prob-
lem of uneven coverage is one of the issues that have to be overcome in next generation se-
quencing. Sanger sequencing of the selected gene panel will be a good choice for small-scale
mutational studies with fewer resources available. However, for the remaining patients without
any positive yield, next generation sequencing is still the choice for identification of other
causative genes.
In the present study, except for the finding of the whole gene deletion of SCN1A and SCN2A
in one patient, all of the MLPA analysis showed negative results for the other 5 genes. Besides,
negative MLPA results have been found for other putative IEE-associated genes including
NRXN1, GRIN2A and GRIN2B in our study (in preparation). As the yield of genetic defects
identified by MLPA was low, we do not suggest trying to identify copy number variations of
IEE-associated genes by MLPA if the resources are limited.
Conclusion
This study highlights that patients with non-syndromal IEE might not have specific pheno-
types to guide candidate gene(s) selection. The yield of mutation analysis of seven selected
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genes of the IEE panel in this group of patients was 42%. Panel approach of genetic testing can
be useful in investigating the underlying cause of IEE that do not fit into any distinct electrocli-
nical syndromes and without any obvious etiologies including neurometabolic diseases.
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